全省药品监督管理工作会议在南京召开

Core Viewpoint - The provincial drug regulatory work meeting highlighted the achievements in drug regulation during 2025 and outlined key tasks for 2026, emphasizing the importance of advancing drug safety and promoting high-quality development in the pharmaceutical industry as part of China's modernization efforts [1][2]. Summary by Sections Achievements in 2025 - The provincial drug regulatory work achieved significant results, ensuring overall drug safety stability and promoting high-quality innovation in the pharmaceutical industry, with the province receiving an A rating in national drug safety assessments [2]. - Strong policy support was provided, including the approval of a comprehensive plan for the open innovation development of the biopharmaceutical industry chain by the State Council and the introduction of 83 reform measures by the provincial government [2]. - Continuous deepening of reforms was noted, with the province leading in the number of newly approved drugs and innovative medical devices, and the establishment of a full-process service mechanism [2]. - Regulatory effectiveness improved, with a drug inspection pass rate maintained at over 99.5% and the establishment of a mechanism for corporate responsibility [2]. - Workforce development was emphasized, with a focus on enhancing the quality of drug regulation personnel and fulfilling central directives [2]. Key Tasks for 2026 - The drug regulatory departments are tasked with implementing the spirit of the 20th National Congress and the 14th Provincial Congress, focusing on high-quality development and efficient governance [3]. - There is a call to strengthen integrated services to optimize the innovation environment for the pharmaceutical industry, enhancing support for drug and medical device development [3]. - Full-chain governance will be reinforced to ensure safety throughout the drug lifecycle, extending governance to more areas including cosmetics [3]. - Modernization of drug regulation will be prioritized, with innovations in regulatory methods and tools to enhance predictability and effectiveness [3]. - Strengthening party leadership and building a high-quality cadre team is essential for guiding the development of drug regulation [3]. Future Focus Areas - The focus will be on deepening reforms, enhancing drug safety, and promoting the pharmaceutical industry's innovation and development [5][6]. - Key areas include advancing comprehensive party governance, deepening drug regulatory reforms, and improving the drug safety regulatory system [5][6]. - The establishment of a risk warning and prevention system is crucial to address potential risks at an early stage [6]. - Continuous enhancement of professional capabilities in drug regulation and the modernization of governance practices will be pursued [6].